ESALF (Eisai Co) Other Current Payables: $0 Mil (As of Mar. 2026)


ESALF Eisai Co Ltd ESALF
74 GF Score
Price $25.00
GF Value $35.73
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Eisai Co Other Current Payables?

Eisai Co ESALF 74 Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.73 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Eisai Co's Other Current Payables for the quarter that ended in Mar. 2026 was $0 Mil.

Eisai Co's annual Other Current Payables declined from Mar. 2024 ($0 Mil) to Mar. 2025 ($0 Mil) but then stayed the same from Mar. 2025 ($0 Mil) to Mar. 2026 ($0 Mil).

Eisai Co Other Current Payables Related Terms

Eisai Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Eisai Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co Other Current Payables Chart

Eisai Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eisai Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ESALF
74GF Score
Eisai Co Ltd ESALF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eisai Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0 Mil mean?
Eisai Co (ESALF) has a Other Current Payables of $0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Eisai Co and its competitors.
Is Eisai Co's Other Current Payables too high?
Eisai Co's current Other Current Payables is $0 Mil. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Other Current Payables compare to ZTS and UTHR?
Eisai Co's Other Current Payables of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Eisai Co and its competitors. Eisai Co's current Other Current Payables is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.73, compared to a current price of $25.00 — trading 30% below its estimated fair value. The current Other Current Payables is $0 Mil. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Eisai Co (ESALF), the current Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eisai Co (ESALF) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of $25.00 is trading 30% below its estimated GF Value™ of $35.73. GuruFocus considers Eisai Co to be Significantly Undervalued.

Key valuation signals for ESALF:

  • Other Current Payables: $0 Mil
  • GF Value™: $35.73 vs. price of $25.00 (30% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score

Get the complete analysis for ESALF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price
$35.73
GF Value